Seven pharmaceutical companies released their semi-annual results on the same day, with some companies increasing their net profit by over 600%!

[Pharmaceutical Network Industry News] On August 29, 7 listed pharmaceutical companies on the Shenzhen Stock Exchange intensively disclosed their 2022 semi-annual reports.
On the whole, there were mixed positives and negatives.
Among the companies that achieved growth in performance, Dongbao Bio had the highest growth rate and net profit in the first half of the year.
A year-on-year increase of more than 600%, reaching 667.
73%
.

Tailin Bio: Net profit increased by 13.
18% year-on-year According to the interim report of Tailin Bio in 2022, the revenue was 146 million yuan, a year-on-year increase of 31.
21%; the net profit was 31.
2988 million yuan, a year-on-year increase of 13.
18%; the basic earnings per share was 0.
38 yuan
.

According to the data, Tailin Bio's main business is the research and development, manufacturing and sales of pharmaceutical equipment such as microbial detection and control technology system products, organic analysis instruments and so on
.

Xingqi Eye Medicine: Net profit increased by 50.
53% year-on-year The 2022 semi-annual report released by Xingqi Eye Medicine shows that during the reporting period, the company achieved operating income of 601 million yuan, a year-on-year increase of 29.
89%; net profit attributable to shareholders of listed companies was 1.
21 100 million yuan, a year-on-year increase of 50.
53%; basic earnings per share were 1.
37 yuan
.

 　　The company stated that during the reporting period, the management of the company actively and orderly promoted and implemented various important tasks based on the annual business plan and goals formulated by the board of directors, encouraged all employees to participate in improvement and innovation, and always firmly followed the road of high-quality and sustainable development
.

 　　Northeast Pharmaceutical: Net profit increased by 86.
46% year-on-year According to the 2022 semi-annual report released by Northeast Pharmaceutical, the company achieved operating income of 4.
420 billion yuan in the first half of the year, a year-on-year increase of 10.
23%, and the net profit attributable to shareholders of the listed company was 113 million yuan, a year-on-year increase of 86.
46 %, and earnings per share were 0.
0835 yuan
.

 　　In the first half of the year, the company's API sales business segment actively formulated differentiated marketing strategies, provided customers with targeted solutions, and added new end customers including large multinational companies
.

The sales of preparations focus on the main business line, seize market opportunities, take indicators as the bottom line, market-oriented, and pure sales as a means to maximize sales and reduce costs and control expenses.
The sales volume of 5 products including VC chewable tablets exceeded the annual sales volume plan
.

 　　Dongbao Bio: Net profit increased by 667.
73% year-on-year According to the 2022 semi-annual report of Dongbao Bio, the operating income was 476 million yuan, a year-on-year increase of 72.
18%; the net profit was 57.
9749 million yuan, a year-on-year increase of 667.
73%
.

 　　As for the reasons for the growth in performance, Dongbao Bio said that in the first half of this year, the company continued to focus on the "collagen +" strategic layout, continued to increase efforts to promote the launch of new terminal series products, and took external investment as the starting point to improve brand and channel construction, establish The three-dimensional sales and promotion network has achieved new breakthroughs in terminal business, and both revenue and net profit have reached a record high
.

 　　Kefu Medical: Net profit decreased by 39.
60% year-on-year According to the 2022 semi-annual report of Kefu Medical, the company achieved operating income of 1.
296 billion yuan from January to June 2022, a year-on-year increase of 17.
84%, and the net profit attributable to shareholders of the listed company was 130 million yuan , down 39.
60% year-on-year, and earnings per share were 0.
6200 yuan
.

 　　According to the data, the company's main business is the research and development, production, sales and service of household medical devices
.

 　　Osaikang: Net profit decreased by 95.
25% year-on-year.
Osaikang released the 2022 semi-annual report.
The company achieved operating income of 1.
011 billion yuan in the first half of the year, a year-on-year decrease of 39.
64%.
The net profit attributable to shareholders of the listed company was 12.
496 million yuan, a year-on-year decrease of 95.
25%.
Earnings per share were 0.
0100 yuan
.

 　　Osaikang said that during the reporting period, the main factors affecting the company's performance included the impact of the centralized drug procurement policy and the impact of the epidemic
.

 　　Aoyuan Meigu: Net profit decreased by 256.
28% year-on-year Aoyuan Meigu's 2022 semi-annual report shows that the company achieved operating income of about 749 million yuan, a year-on-year decrease of 35.
81%; net profit attributable to shareholders of the listed company was -78.
34 million yuan, a year-on-year A decrease of 256.
28%
.

 　　According to the data, the company's main business is fiber new material business and medical beauty business
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.